Sep 20

abopharm

Flu Vaccines

You can now Order Flu Vaccine Online at www.shopfluvaccines.com

You can now Order Flu Vaccine Online at our Flu Vaccine website

www.shopfluvaccines.com

CLICK HERE TO ORDER FLU VACCINE

Read On

Jul 01

abopharm

Flu Vaccines Influenza Pharmaceutical News PPE vaccines

ABO Pharmaceuticals is NABP accredited drug distributor – VAWD

NABP ACCREDITED DRUG DISTRIBUTOR

This business has met all the drug distributor criteria set in place by the National Association of Boards of Pharmacy® (NABP®). The current status of this business’s accreditation may also be verified by visiting the drug distributor section on the NABP website, located at: www.nabp.pharmacy/programs/drug-distributor/accredited-facilities/.

ABO VAWD Certificate 2020 – 2023

Read On

Apr 28

abopharm

Flu Vaccines Influenza vaccines

Recommended composition of influenza virus vaccines for use in the 2022-2023 northern hemisphere influenza season

The WHO recommends that quadrivalent vaccines for use in the 2022-2023 northern hemisphere influenza season contain the following:

Egg-based vaccines

an A/Victoria/2570/2019 (H1N1)pdm09-like virus;
an A/Darwin/9/2021 (H3N2)-like virus;
a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and
a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

Cell culture- or recombinant-based vaccines

an A/Wisconsin/588/2019 (H1N1)pdm09-like virus;
an A/Darwin/6/2021 (H3N2)-like virus;
a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and
a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

The WHO recommends that trivalent vaccines for use in the 2022-2023 northern hemisphere influenza season contain the following:

Egg-based vaccines

an A/Victoria/2570/2019 (H1N1)pdm09-like virus;
an A/Darwin/9/2021 (H3N2)-like virus; and
a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.

Cell culture- or recombinant-based vaccines

an A/Wisconsin/588/2019 (H1N1)pdm09-like virus;
an A/Darwin/6/2021 (H3N2)-like virus; and
a B/Austria/1359417/2021 (B/Victoria lineage)-like virus

202202_recommendation

Read On

Apr 28

abopharm

Flu Vaccines

ABO Pharmaceuticals Listed as AUTHORIZED BYD Distributor

AUTHORIZED BYD DEALERS

https://www.byd.care/blogs/news6/authorized-byd-dealers

April 27, 2021

BYD Care is happy to announce a partnership with TBG Tech Co. and Dream Medical Group, LLC as authorized dealers and partners in the sales and service of BYD Care products to U.S. customers including federal, state and local government agencies and large hospital chains

‘BYD Care’s highest priority is to make sure our customers have direct access to high quality, safe and reliable BYD Care products,” said Stella Li, BYD’s President, North America. Our partnership with TBG and Dream Medical Group ensures that.”

TBG and Dream Medical Group offer their customers warehouse and inventory control, financial services and local customer support in their role as BYD’s official distributor to government agencies and larger hospital chains.

Other BYD official partners include Office Depot, ABO Pharmaceuticals, Henry Schein and Cardinal Health, servicing the medical industry, smaller hospitals and nursing homes.

Read On

Mar 27

abopharm

Flu Vaccines

COVID-19 ABO response

In these uncertain times, ABO Pharmaceuticals would like to keep you informed of our operational status, the status of your current orders, and our continued ability to support our customer’s needs.
ABO Pharmaceuticals recognizes the important role that our organization plays in keeping our customers stocked and in operation, especially during these challenging times as the world navigates the rapidly evolving corona virus (COVID-19) situation. We wanted to contact you to keep you apprised of the extra precautions we are taking at ABO to ensure that our team is able to keep themselves healthy and able to serve you, our valued customers.
Our Team Is Working ABO Pharmaceuticals offices continue to be open and operating normally. All orders in progress are being prepared in our warehouse and shipments continue to go out domestically and globally and we intend to maintain this status unless otherwise notified. Our office has taken a higher level of cleaning/sanitizing of all significant open spots to reduce the spread of germs and hopefully minimize the impact on our staff.
Here to Support Your Needs During this period, your ABO Sales team member will be able to assist you from our sales offices, and if remote work is necessary, we are capable to work from home by phone, video conference and email. Further, our logistics partners ensure us that land, sea, and air freight will still move as needed to deliver all your pharmaceutical needs.
One Call Away Overall, we continue to provide all our normal services. Should you have any questions or urgent needs, please contact your ABO Team Member directly or call our Toll-Free Phone: 877-226-2266. Email also available at info@abopharmaceuticals.com
Thank you for the opportunity to continue to earn your business. We wish you the best of health and hope that you will take the necessary health precautions as recommended by the health authorities to keep you, your colleagues, and your families out of harm’s way!
Stay Safe, Stay Healthy

ABO Pharmaceuticals

Read On

Mar 10

abopharm

Flu Vaccines

Recommended composition of influenza virus vaccines for use in the 2020 – 2021 northern hemisphere influenza season

Recommended composition of influenza virus vaccines for use in the 2020 – 2021 northern hemisphere influenza season
28 February 2020
It is recommended that quadrivalent vaccines for use in the 2020 – 2021 northern hemisphere influenza season contain the following:

Egg-based Vaccines

an A/Guangdong-Maonan/SWL1536/2019 (H1N1)pdm09-like virus;
an A/Hong Kong/2671/2019 (H3N2)-like virus;
a B/Washington/02/2019 (B/Victoria lineage)-like virus; and
a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.
Cell- or recombinant-based Vaccines

an A/Hawaii/70/2019 (H1N1)pdm09-like virus;
an A/Hong Kong/45/2019 (H3N2)-like virus;
a B/Washington/02/2019 (B/Victoria lineage)-like virus; and
a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.
It is recommended that trivalent influenza vaccines for use in the 2020 – 2021 northern hemisphere influenza season contain the following:

Egg-based Vaccines

an A/Guangdong-Maonan/SWL1536/2019 (H1N1)pdm09-like virus;
an A/Hong Kong/2671/2019 (H3N2)-like virus; and
a B/Washington/02/2019 (B/Victoria lineage)-like virus.
Cell- or recombinant-based Vaccines

an A/Hawaii/70/2019 (H1N1)pdm09-like virus;
an A/Hong Kong/45/2019 (H3N2)-like virus; and
a B/Washington/02/2019 (B/Victoria lineage)-like virus.

Read On

Mar 10

abopharm

Flu Vaccines

Recommended composition of influenza virus vaccines for use in the 2020 – 2021 northern hemisphere influenza season

Egg-based Vaccines

an A/Guangdong-Maonan/SWL1536/2019 (H1N1)pdm09-like virus;
an A/Hong Kong/2671/2019 (H3N2)-like virus; and
a B/Washington/02/2019 (B/Victoria lineage)-like virus.
Cell- or recombinant-based Vaccines

an A/Hawaii/70/2019 (H1N1)pdm09-like virus;
an A/Hong Kong/45/2019 (H3N2)-like virus; and
a B/Washington/02/2019 (B/Victoria lineage)-like virus.

Read On

Mar 10

abopharm

Flu Vaccines

Recommended composition of influenza virus vaccines for use in the 2020 – 2021 northern hemisphere influenza season

Egg-based Vaccines

an A/Guangdong-Maonan/SWL1536/2019 (H1N1)pdm09-like virus;
an A/Hong Kong/2671/2019 (H3N2)-like virus; and
a B/Washington/02/2019 (B/Victoria lineage)-like virus.
Cell- or recombinant-based Vaccines

an A/Hawaii/70/2019 (H1N1)pdm09-like virus;
an A/Hong Kong/45/2019 (H3N2)-like virus; and
a B/Washington/02/2019 (B/Victoria lineage)-like virus.

Read On

Aug 01

Web Master

Flu Vaccines

WHO Strain Recommendations for 2018-2019 Flu Vaccine

The World Health Organization (WHO) recommends that quadrivalent vaccines for use in the 2018-2019 northern hemisphere influenza season contain the following:

an A/Michigan/45/2015 (H1N1)pdm09-like virus;
an A/Singapore/INFIMH-16-0019/2016 (H3N2)-like virus;
a B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage); and
a B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage).

WHO also recommends that the influenza B virus component of trivalent vaccines for use in the 2018-2019 northern hemisphere influenza season be a B/Colorado/06/2017-like virus of the B/Victoria/2/87-lineage.

For more information, visit:

This recommendation by WHO was reviewed by the U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) and approval was given to adopt these recommendations for the 2018-2019 influenza vaccine strains.

The final VRBPAC decision allows vaccine manufacturers to start formulating the upcoming seasonal flu vaccine, a process that takes about 6 months.

Read On

Mar 14

Web Master

Flu Vaccine 2017-2018 Flu Vaccines Influenza vaccines

Recommended composition of influenza virus vaccines for use in the 2017- 2018 northern hemisphere influenza season

Recommended composition of influenza virus vaccines for use in the 2017-
2018 northern hemisphere influenza season

March 2017

Recommended composition of influenza virus vaccines for use in the 2017-2018
northern hemisphere influenza season
Influenza A(H3N2) viruses predominated in most countries, with low levels of A(H1N1)pdm09 and
influenza B viruses also circulating during the period September 2016 – February 2017.
Influenza A(H1N1)pdm09 viruses were antigenically indistinguishable by post-infection ferret
antisera raised against current vaccine viruses A/California/7/2009 and A/Michigan/45/2015.
However, representative circulating viruses were poorly inhibited by some post-vaccination adult
human serum pools.
Influenza A(H3N2) viruses were associated with outbreaks in many countries. The majority of recent
viruses were antigenically related to cell culture-propagated 3C.2a A/Hong Kong/4801/2014-like
viruses. A(H3N2) viruses within the 3C.2a clade have become genetically diverse, although they
remain antigenically similar. The majority of recently circulating A(H3N2) viruses belong to subclade
3C.2a1.
Influenza B viruses of the B/Victoria/2/87 and the B/Yamagata/16/88 lineages co-circulated at
similar levels in some regions, but in many countries in South America, Asia and Eastern Europe,
B/Victoria/2/87 lineage viruses were predominant. Most B/Victoria/2/87 lineage viruses were
antigenically and genetically closely related to B/Brisbane/60/2008 and B/Texas/2/2013. The majority
of recent B/Yamagata/16/88 lineage viruses were antigenically and genetically closely related to
B/Phuket/3073/2013.
It is recommended that trivalent vaccines for use in the 2017-2018 northern hemisphere
influenza season contain the following:
– an A/Michigan/45/2015 (H1N1)pdm09-like virus;
– an A/Hong Kong/4801/2014 (H3N2)-like virus; and
– a B/Brisbane/60/2008-like virus.
It is recommended that quadrivalent vaccines containing two influenza B viruses contain the
above three viruses and a B/Phuket/3073/2013-like virus.
Lists of egg- or cell culture-propagated candidate vaccine viruses (CVVs) suitable for use in human
vaccine production are available on the WHO website3
. A list of reagents for vaccine standardisation,
including those for this recommendation, can also be found on the WHO website. CVVs for zoonotic
influenza viruses are listed on the same website.

The World Health Organization (WHO) convenes technical consultations1 in February/March and
September each year to recommend viruses for inclusion in influenza vaccines2 for the northern and
southern hemisphere influenza seasons, respectively. This recommendation relates to the influenza
vaccines for use in the forthcoming northern hemisphere 2017-2018 influenza season. A
recommendation will be made in September 2017 relating to vaccines that will be used for the
southern hemisphere 2018 influenza season. For countries in tropical and subtropical regions,
epidemiological considerations influence which recommendation (northern hemisphere or southern
hemisphere) individual national and regional authorities consider appropriate.
Seasonal influenza activity, September 2016 – February 2017
Between September 2016 and February 2017 influenza activity was reported in Africa, the Americas,
Asia, Europe and Oceania. In general, activity was higher compared with the same period last year. In
the southern hemisphere, influenza activity was low in most countries, however, regional outbreaks
continued in South Africa during September and in Australia during September and October. In the
northern hemisphere, influenza activity began in Asia and Europe in October-November and had
increased in most countries by December. In many countries with tropical and subtropical climates,
influenza circulated during the entire reporting period.
Influenza A(H1N1)pdm09 viruses circulated at very low levels with a few exceptions. Influenza
A(H3N2) viruses were dominant in most countries and regional and widespread outbreaks were
reported in Asia, Europe, and North America. Influenza B viruses circulated at low levels in most
countries throughout the period while regional outbreaks were reported in Asia, western Africa and
the United States of America

Read On